DCP
BSX icon

DSM Capital Partners’s Boston Scientific BSX Stock Holding History

DSM Capital Partners’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.9M Sell
511,968
-52,381
-9% -$2.84M 0.37% 31
2026
Q1 		$35.4M Buy
564,349
+559,625
+11,846% +$44.8M 0.63% 26
2025
Q4 		$450K Buy
4,724
+747
+19% +$73.2K 0.01% 36
2025
Q3 		$388K Buy
3,977
+1,119
+39% +$116K 0.01% 37
2025
Q2 		$307K Buy
+2,858
New +$289K ﹤0.01% 37
2024
Q4 		– Sell
-1,324
Closed -$111K – 52
2024
Q3 		$111K Hold
1,324
– – ﹤0.01% 46
2024
Q2 		$102K Sell
1,324
-2,167,681
-100% -$159M ﹤0.01% 45
2024
Q1 		$149M Sell
2,169,005
-669,618
-24% -$43.1M 2.03% 18
2023
Q4 		$164M Buy
2,838,623
+444,794
+19% +$23.7M 2.51% 14
2023
Q3 		$126M Sell
2,393,829
-96,116
-4% -$5.04M 2.13% 19
2023
Q2 		$135M Sell
2,489,945
-1,162,600
-32% -$60.7M 2.18% 17
2023
Q1 		$183M Sell
3,652,545
-1,347,768
-27% -$63.5M 2.99% 14
2022
Q4 		$231M Sell
5,000,313
-590,902
-11% -$25.6M 3.85% 10
2022
Q3 		$217M Buy
5,591,215
+294,050
+6% +$11.8M 3.67% 9
2022
Q2 		$197M Buy
5,297,165
+268,026
+5% +$10.9M 3.31% 8
2022
Q1 		$223M Buy
5,029,139
+1,174,491
+30% +$50.9M 2.98% 9
2021
Q4 		$164M Sell
3,854,648
-271,157
-7% -$11.4M 1.72% 19
2021
Q3 		$179M Buy
4,125,805
+501,060
+14% +$22.2M 1.86% 16
2021
Q2 		$155M Buy
3,624,745
+465,847
+15% +$19.6M 1.49% 24
2021
Q1 		$122M Buy
3,158,898
+167,679
+6% +$6.35M 1.3% 24
2020
Q4 		$108M Buy
2,991,219
+480,339
+19% +$17.3M 1.15% 24
2020
Q3 		$95.9M Buy
2,510,880
+447,561
+22% +$17.2M 1.07% 22
2020
Q2 		$72.4M Sell
2,063,319
-1,554,378
-43% -$56M 0.86% 26
2020
Q1 		$118M Buy
3,617,697
+1,335,632
+59% +$52.2M 1.79% 17
2019
Q4 		$103M Buy
+2,282,065
New +$95.5M 1.37% 25

Other funds holding BSX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

DSM Capital Partners's BSX Position: Q2 2026 in Review

DSM Capital Partners reduced its Boston Scientific (BSX) stake by 9.3% in Q2 2026, selling an estimated $2.84M and leaving 511,968 shares worth $21.9M. The position accounts for 0.37% of the portfolio, ranked #31.

DSM Capital Partners first reported a position in BSX in Q4 2019 and has held it in 25 quarters since. The position peaked at $231M in Q4 2022. 1,474 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • DSM Capital Partners held 511,968 shares of Boston Scientific worth $21.9M as of Q2 2026.
  • DSM Capital Partners sold 52,381 Boston Scientific shares in Q2 2026, an estimated $2.84M.
  • Boston Scientific made up 0.37% of DSM Capital Partners's portfolio in Q2 2026, its #31 holding.
  • DSM Capital Partners first reported a position in Boston Scientific in Q4 2019 and has held it in 25 quarters since.
  • DSM Capital Partners's Boston Scientific position peaked at $231M in Q4 2022.
  • 1,474 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on DSM Capital Partners's 13F filing for Q2 2026, filed 3 Aug 2026.